Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$58.65

-0.19 (-0.32%)

16:38
04/13/18
04/13
16:38
04/13/18
16:38

Bristol-Myers reports 'positive' results from Phase 3 CheckMate -078 trial

Bristol-Myers announced results from the pivotal, randomized Phase 3 CheckMate -078 trial evaluating Opdivo versus docetaxel in a predominantly Chinese population with previously treated advanced non-small cell lung cancer. In the study, Opdivo demonstrated a statistically significant benefit versus docetaxel on the primary endpoint of overall survival. An OS benefit was observed regardless of PD-L1 expression or tumor histology. Additionally, the two secondary endpoints of objective response rate and median duration of response demonstrated durability with Opdivo compared with docetaxel. In CheckMate -078, Grade 3-4 treatment-related adverse events occurred less frequently with Opdivo versus docetaxel (10% vs 47%). Discontinuation due to Grade 3-4 TRAEs were less frequent with Opdivo (3%) than with docetaxel (5%). Findings will be presented on Monday, April 16 from 4:05-4:20 PM CDT during the Updates in Immuno-Oncology Trials session at the American Association for Cancer Research Annual Meeting 2018 in Chicago.

  • 14

    Apr

  • 26

    Apr

  • 08

    May

  • 21

    May

  • 10

    Jul

BMY Bristol-Myers
$58.65

-0.19 (-0.32%)

04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.

TODAY'S FREE FLY STORIES

AGRO

Adecogro

$8.41

0.05 (0.60%)

07:47
07/17/18
07/17
07:47
07/17/18
07:47
Initiation
Adecogro initiated  »

Adecogro initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

07:46
07/17/18
07/17
07:46
07/17/18
07:46
Technical Analysis
Technical Take: Netflix off worst post-earnings levels in early trading »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRS

Aclaris Therapeutics

$20.49

-0.11 (-0.53%)

, LLY

Eli Lilly

$89.06

-0.64 (-0.71%)

07:45
07/17/18
07/17
07:45
07/17/18
07:45
Recommendations
Aclaris Therapeutics, Eli Lilly, Pfizer analyst commentary  »

Aclaris offers best…

ACRS

Aclaris Therapeutics

$20.49

-0.11 (-0.53%)

LLY

Eli Lilly

$89.06

-0.64 (-0.71%)

PFE

Pfizer

$37.39

-0.14 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 22

    Aug

  • 10

    Sep

NEWR

New Relic

$109.01

0.35 (0.32%)

07:39
07/17/18
07/17
07:39
07/17/18
07:39
Initiation
New Relic initiated  »

New Relic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:38
07/17/18
07/17
07:38
07/17/18
07:38
Hot Stocks
Goldman Sachs reports Q2 FICC revenue $1.68B, 45% higher than last year »

Net revenues in Fixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$36.92

3 (8.84%)

07:38
07/17/18
07/17
07:38
07/17/18
07:38
Technical Analysis
Technical Take: iQIYI falls, completes Skymoons acquisition »

The shares of iQIYI (IQ)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCR

Novocure

$35.60

2.5 (7.55%)

07:37
07/17/18
07/17
07:37
07/17/18
07:37
Hot Stocks
Novocure announces scientific track for tumor treating fields at EMBS »

Novocure announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

RVI

Retail Value

$35.60

-0.36 (-1.00%)

, DDR

DDR Corp.

$14.31

-0.045 (-0.31%)

07:36
07/17/18
07/17
07:36
07/17/18
07:36
Initiation
Retail Value, DDR Corp. initiated  »

Retail Value initiated…

RVI

Retail Value

$35.60

-0.36 (-1.00%)

DDR

DDR Corp.

$14.31

-0.045 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:36
07/17/18
07/17
07:36
07/17/18
07:36
Hot Stocks
Goldman Sachs reports Q2 annualized ROE 12.8% »

Annualized return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$2.64

-0.12 (-4.35%)

07:35
07/17/18
07/17
07:35
07/17/18
07:35
Hot Stocks
22nd Century comments on FDA's ANPRM to lessen nicotine in cigarettes »

22nd Century responded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

, MSFT

Microsoft

$104.91

-0.51 (-0.48%)

07:35
07/17/18
07/17
07:35
07/17/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

NFLX

Netflix

$400.24

4.32 (1.09%)

MSFT

Microsoft

$104.91

-0.51 (-0.48%)

SNAP

Snap

$13.07

-0.295 (-2.21%)

FOXA

21st Century Fox

$46.71

-0.84 (-1.77%)

MS

Morgan Stanley

$48.91

0.85 (1.77%)

TGT

Target

$77.20

-0.525 (-0.68%)

FSLR

First Solar

$53.99

-0.08 (-0.15%)

CZR

Caesars

$11.63

0.075 (0.65%)

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

HFC

HollyFrontier

$68.91

0.25 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

BCRX

BioCryst

$6.20

0.01 (0.16%)

07:34
07/17/18
07/17
07:34
07/17/18
07:34
Upgrade
BioCryst rating change  »

BioCryst upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

07:33
07/17/18
07/17
07:33
07/17/18
07:33
Earnings
Goldman Sachs reports Q2 EPS $5.98, consensus $4.66 »

Reports Q2 revenue $9.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

, LB

L Brands

$32.01

0.31 (0.98%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Columbus signs renewal agreement with Victoria's Secret »

Alliance Data Systems…

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

LB

L Brands

$32.01

0.31 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

PRIM

Primoris

$28.12

-0.51 (-1.78%)

07:32
07/17/18
07/17
07:32
07/17/18
07:32
Hot Stocks
Primoris announces electrical distribution award valued over $75M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$41.10

1.38 (3.47%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Recommendations
Zscaler analyst commentary  »

Zscaler price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

, QEP

QEP Resources

$12.09

-0.67 (-5.25%)

07:30
07/17/18
07/17
07:30
07/17/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

TSRO

Tesaro

$40.55

-4.34 (-9.67%)

QEP

QEP Resources

$12.09

-0.67 (-5.25%)

HUBG

Hub Group

$49.10

-1.85 (-3.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 19

    Aug

RPM

RPM

$60.00

-0.54 (-0.89%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Downgrade
RPM rating change  »

RPM downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

OSUR

OraSure

$16.28

-1.04 (-6.00%)

07:27
07/17/18
07/17
07:27
07/17/18
07:27
Recommendations
OraSure analyst commentary  »

OraSure weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

07:26
07/17/18
07/17
07:26
07/17/18
07:26
Recommendations
Netflix analyst commentary  »

Canaccord views Netflix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

07:25
07/17/18
07/17
07:25
07/17/18
07:25
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$30.58

-0.36 (-1.16%)

07:24
07/17/18
07/17
07:24
07/17/18
07:24
Initiation
TechnipFMC initiated  »

TechnipFMC assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

QTS

QTS Realty Trust

$40.90

-0.05 (-0.12%)

07:23
07/17/18
07/17
07:23
07/17/18
07:23
Initiation
QTS Realty Trust initiated  »

QTS Realty Trust resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BA

Boeing

$356.01

5.2 (1.48%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Hot Stocks
Boeing signs integrated services agreement with Blackshape »

Boeing announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Oppenheimer remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.